Antiviral therapy in pregnancy

Area of Science:

• Medical Science
• Virology
• Obstetrics

Background:

• Limited clinical experience exists regarding zidovudine use in human pregnancies.
• Acquired Immunodeficiency Syndrome (AIDS) and AIDS-Related Complex (ARC) pose significant health risks to pregnant individuals.
• Perinatal transmission of Human Immunodeficiency Virus (HIV) remains a critical concern.

Purpose of the Study:

• To evaluate the current recommendations for zidovudine therapy in pregnant women diagnosed with HIV.
• To assess the potential risks and benefits of zidovudine treatment during pregnancy.
• To determine the necessity of further research on zidovudine's role in preventing mother-to-child HIV transmission.

Main Methods:

• Review of existing clinical data and expert opinion on zidovudine use in pregnancy.
• Analysis of the implications of withholding zidovudine therapy for pregnant women with HIV.
• Consideration of standard dosage and monitoring protocols for zidovudine administration during gestation.

Main Results:

• It is currently considered unreasonable to withhold zidovudine therapy from pregnant women with AIDS/ARC due to fetal concerns.
• The efficacy of zidovudine in reducing perinatal HIV transmission is currently unknown and requires controlled trials.
• Standard dosage (200 mg every 4 hours) is recommended if zidovudine therapy is necessary during pregnancy.

Conclusions:

• Zidovudine therapy should not be withheld from pregnant women with AIDS/ARC based on current limited data.
• Further controlled trials are necessary to establish the role of zidovudine in preventing perinatal HIV transmission.
• Pregnant women receiving zidovudine require close monitoring for potential maternal and fetal toxicity.